| 产品描述: | STING agonist-17 (compound 4a) is a potent STING agonist with an IC50 value of 0.062 nM. STING agonist-17 has anti-cancer activity for tumor immunization. |
| 体外研究: |
STING agonist-17 (compound 4a) (Intravenous injection; 0.015 mg/kg, 1.5 mg/kg; every other day; a week) has an inhibitory effect on tumor growth in CT26 cells-derived colon carcinoma female BALB/c mice[1]. The pharmacokinetic parameters of Compound 4a in vivo[1]. |
| 体内研究: |
STING agonist-17 (compound 4a) inhibits the activity of four major CYP isozymes (CYP1A2, CYP2C9, CYP2C19 and CYP2D6) with IC50 values > 100 μM and for CYP3A4 with an IC50 = 4.2 μM. STING agonist-17 (compound 4a) (0-2 μM, 24 hours) induces IFN-β secretion with the EC50 of 2.0 nM. STING agonist-17 (compound 4a) (2 nM, 10 nM, 6 hours) can induce the expression of signal transduction factors. The pharmacokinetic parameters of Compound 4a in vitro. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.136 ml |
5.682 ml |
11.364 ml |
| 5 mM |
0.227 ml |
1.136 ml |
2.273 ml |
| 10 mM |
0.114 ml |
0.568 ml |
1.136 ml |
| 50 mM |
0.023 ml |
0.114 ml |
0.227 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |